Faruqi & Faruqi, LLP Obtains Significant Victories On Behalf Of Investors In In re Geron Corporation Securities Litigation
On April 10, 2015, United States District Judge Charles Breyer denied, in part, a motion to dismiss filed by Geron Corporation (“Geron”), Chief Executive Officer John A. Scarlett, Chief Financial Officer Olivia K. Bloom, and former Chief Medical Officer Stephen M. Kelsey (together “Defendants”). The Court sustained claims alleging that the Defendants violated the federal securities laws by making materially false and misleading statements regarding the safety of Geron’s cancer drug, imetelstat, and the follow-up procedures for Geron’s Phase 2 trial of imetelstat in patients with Essential Thrombocythemia and Polycythemia Vera. The Court also sustained claims alleging that Scarlett, Bloom, and Kelsey acted as control persons of Geron.
If you purchased Geron common stock between December 10, 2012 and March 11, 2014, inclusive, and would like to discuss your legal rights, call Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or send an e-mail to email@example.com.